- Home
- FMAC vs TLSA Comparison
FMAC vs TLSA Comparison
Compare FMAC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMAC | TLSA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 155.3M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FMAC | TLSA |
|---|---|---|
| Price | $10.00 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 193.3K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $1.04 |
| 52 Week High | $10.02 | $2.60 |
Technical Indicators
Market Signals| Indicator | FMAC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 48.02 |
| Support Level | N/A | $1.14 |
| Resistance Level | N/A | $1.44 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 71.43 | 52.15 |
Price Performance
Historical ComparisonAbout FMAC Future Money Acquisition Corporation Ordinary Shares
Future Money Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.